TY - JOUR AU - Lynch, T. J. AU - Bell, D. W. AU - Sordella, R. AU - Gurubhagavatula, S. AU - Okimoto, R. A. AU - Brannigan, B. W. PY - 2004 DA - 2004// TI - Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib JO - N Engl J Med VL - 350 UR - https://doi.org/10.1056/NEJMoa040938 DO - 10.1056/NEJMoa040938 ID - Lynch2004 ER - TY - JOUR AU - Pao, W. AU - Miller, V. AU - Zakowski, M. AU - Doherty, J. AU - Politi, K. AU - Sarkaria, I. PY - 2004 DA - 2004// TI - EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib JO - Proc Natl Acad Sci U S A VL - 101 UR - https://doi.org/10.1073/pnas.0405220101 DO - 10.1073/pnas.0405220101 ID - Pao2004 ER - TY - JOUR AU - Paez, J. G. AU - Jänne, P. A. AU - Lee, J. C. AU - Tracy, S. AU - Greulich, H. AU - Gabriel, S. PY - 2004 DA - 2004// TI - EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy JO - Science VL - 304 UR - https://doi.org/10.1126/science.1099314 DO - 10.1126/science.1099314 ID - Paez2004 ER - TY - JOUR AU - Mitsudomi, T. AU - Yatabe, Y. PY - 2010 DA - 2010// TI - Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer JO - FEBS J VL - 277 UR - https://doi.org/10.1111/j.1742-4658.2009.07448.x DO - 10.1111/j.1742-4658.2009.07448.x ID - Mitsudomi2010 ER - TY - JOUR AU - Ladanyi, M. AU - Pao, W. PY - 2008 DA - 2008// TI - Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond JO - Mod Pathol VL - 21 UR - https://doi.org/10.1038/modpathol.3801018 DO - 10.1038/modpathol.3801018 ID - Ladanyi2008 ER - TY - JOUR AU - Fukuoka, M. AU - Wu, Y. -. L. AU - Thongprasert, S. AU - Sunpaweravong, P. AU - Leong, S. -. S. AU - Sriuranpong, V. PY - 2011 DA - 2011// TI - Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non–small-cell lung cancer in Asia (IPASS) JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.33.4235 DO - 10.1200/JCO.2010.33.4235 ID - Fukuoka2011 ER - TY - STD TI - C. Zhou, Y.-L. Wu, G. Chen, J. Feng, X.-Q. Liu, C. Wang, et al, "Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study," Lancet Oncol, 12, 735–742, 2011. ID - ref7 ER - TY - JOUR AU - Rosell, R. AU - Carcereny, E. AU - Gervais, R. AU - Vergnenegre, A. AU - Massuti, B. AU - Felip, E. PY - 2012 DA - 2012// TI - Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial JO - Lancet Oncol VL - 13 UR - https://doi.org/10.1016/S1470-2045(11)70393-X DO - 10.1016/S1470-2045(11)70393-X ID - Rosell2012 ER - TY - JOUR AU - Wu, Y. -. L. AU - Zhou, C. AU - Liam, C. -. K. AU - Wu, G. AU - Liu, X. AU - Zhong, Z. PY - 2015 DA - 2015// TI - First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study JO - Ann Oncol VL - 26 UR - https://doi.org/10.1093/annonc/mdv270 DO - 10.1093/annonc/mdv270 ID - Wu2015 ER - TY - JOUR AU - Han, J. -. Y. AU - Park, K. AU - Kim, S. -. W. AU - Lee, D. H. AU - Kim, H. Y. AU - Kim, H. T. PY - 2012 DA - 2012// TI - First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.36.8456 DO - 10.1200/JCO.2011.36.8456 ID - Han2012 ER - TY - JOUR AU - Mok, T. S. AU - Wu, Y. -. L. AU - Thongprasert, S. AU - Yang, C. -. H. AU - Chu, D. -. T. AU - Saijo, N. PY - 2009 DA - 2009// TI - Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma JO - N Engl J Med VL - 361 UR - https://doi.org/10.1056/NEJMoa0810699 DO - 10.1056/NEJMoa0810699 ID - Mok2009 ER - TY - JOUR AU - Maemondo, M. AU - Inoue, A. AU - Kobayashi, K. AU - Sugawara, S. AU - Oizumi, S. AU - Isobe, H. PY - 2010 DA - 2010// TI - Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR JO - N Engl J Med VL - 362 UR - https://doi.org/10.1056/NEJMoa0909530 DO - 10.1056/NEJMoa0909530 ID - Maemondo2010 ER - TY - JOUR AU - Mitsudomi, T. AU - Morita, S. AU - Yatabe, Y. AU - Negoro, S. AU - Okamoto, I. AU - Tsurutani, J. PY - 2010 DA - 2010// TI - Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial JO - Lancet Oncol VL - 11 UR - https://doi.org/10.1016/S1470-2045(09)70364-X DO - 10.1016/S1470-2045(09)70364-X ID - Mitsudomi2010 ER - TY - JOUR AU - Arcila, M. E. AU - Nafa, K. AU - Chaft, J. E. AU - Rekhtman, N. AU - Lau, C. AU - Reva, B. A. PY - 2013 DA - 2013// TI - EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics JO - Mol Cancer Ther VL - 12 UR - https://doi.org/10.1158/1535-7163.MCT-12-0620 DO - 10.1158/1535-7163.MCT-12-0620 ID - Arcila2013 ER - TY - JOUR AU - Yasuda, H. AU - Kobayashi, S. AU - Costa, D. B. PY - 2012 DA - 2012// TI - EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications JO - Lancet Oncol VL - 13 UR - https://doi.org/10.1016/S1470-2045(11)70129-2 DO - 10.1016/S1470-2045(11)70129-2 ID - Yasuda2012 ER - TY - JOUR AU - Oxnard, G. R. AU - Lo, P. C. AU - Nishino, M. AU - Dahlberg, S. E. AU - Lindeman, N. I. AU - Butaney, M. PY - 2013 DA - 2013// TI - Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions JO - J Thorac Oncol VL - 8 UR - https://doi.org/10.1097/JTO.0b013e3182779d18 DO - 10.1097/JTO.0b013e3182779d18 ID - Oxnard2013 ER - TY - JOUR AU - Yasuda, H. AU - Park, E. AU - Yun, C. -. H. AU - Sng, N. J. AU - Lucena-Araujo, A. R. AU - Yeo, W. -. L. PY - 2013 DA - 2013// TI - Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer JO - Sci Transl Med VL - 5 UR - https://doi.org/10.1126/scitranslmed.3007205 DO - 10.1126/scitranslmed.3007205 ID - Yasuda2013 ER - TY - JOUR AU - Inukai, M. AU - Toyooka, S. AU - Ito, S. AU - Asano, H. AU - Ichihara, S. AU - Soh, J. PY - 2006 DA - 2006// TI - Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non–small cell lung cancer JO - Cancer Res VL - 66 UR - https://doi.org/10.1158/0008-5472.CAN-06-1951 DO - 10.1158/0008-5472.CAN-06-1951 ID - Inukai2006 ER - TY - JOUR AU - Pao, W. AU - Miller, V. A. AU - Politi, K. A. AU - Riely, G. J. AU - Somwar, R. AU - Zakowski, M. F. PY - 2005 DA - 2005// TI - Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain JO - PLoS Med VL - 2 UR - https://doi.org/10.1371/journal.pmed.0020073 DO - 10.1371/journal.pmed.0020073 ID - Pao2005 ER - TY - JOUR AU - Kobayashi, S. AU - Boggon, T. J. AU - Dayaram, T. AU - Jänne, P. A. AU - Kocher, O. AU - Meyerson, M. PY - 2005 DA - 2005// TI - EGFR mutation and resistance of non–small-cell lung cancer to gefitinib JO - N Engl J Med VL - 352 UR - https://doi.org/10.1056/NEJMoa044238 DO - 10.1056/NEJMoa044238 ID - Kobayashi2005 ER - TY - JOUR AU - Taron, M. AU - Ichinose, Y. AU - Rosell, R. AU - Mok, T. AU - Massuti, B. AU - Zamora, L. PY - 2005 DA - 2005// TI - Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas JO - Clin Cancer Res VL - 11 UR - https://doi.org/10.1158/1078-0432.CCR-04-2618 DO - 10.1158/1078-0432.CCR-04-2618 ID - Taron2005 ER - TY - JOUR AU - Rosell, R. AU - Ichinose, Y. AU - Taron, M. AU - Sarries, C. AU - Queralt, C. AU - Mendez, P. PY - 2005 DA - 2005// TI - Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer JO - Lung Cancer VL - 50 UR - https://doi.org/10.1016/j.lungcan.2005.05.017 DO - 10.1016/j.lungcan.2005.05.017 ID - Rosell2005 ER - TY - JOUR AU - Han, S. -. W. AU - Kim, T. -. Y. AU - Hwang, P. G. AU - Jeong, S. AU - Kim, J. AU - Choi, I. S. PY - 2005 DA - 2005// TI - Predictive and prognostic impact of epidermal growth factor receptor mutation in non–small-cell lung cancer patients treated with gefitinib JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.01.388 DO - 10.1200/JCO.2005.01.388 ID - Han2005 ER - TY - JOUR AU - Kobayashi, Y. AU - Togashi, Y. AU - Yatabe, Y. AU - Mizuuchi, H. AU - Jangchul, P. AU - Kondo, C. PY - 2015 DA - 2015// TI - EGFR exon 18 mutations in lung cancer: molecular predictors of augmented sensitivity to afatinib or neratinib as compared with first-or third-generation TKIs JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-15-1046 DO - 10.1158/1078-0432.CCR-15-1046 ID - Kobayashi2015 ER - TY - JOUR AU - Beau-Faller, M. AU - Prim, N. AU - Ruppert, A. -. M. AU - Nanni-Metéllus, I. AU - Lacave, R. AU - Lacroix, L. PY - 2014 DA - 2014// TI - Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network JO - Ann Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdt418 DO - 10.1093/annonc/mdt418 ID - Beau-Faller2014 ER - TY - STD TI - Cheng C, Wang R, Li Y, Pan Y, Zhang Y, Li H, et al. EGFR exon 18 mutations in east Asian patients with lung adenocarcinomas: a comprehensive investigation of prevalence, clinicopathologic characteristics and prognosis. Sci Rep. 2015;5:13959. https://www.nature.com/articles/srep13959. UR - https://www.nature.com/articles/srep13959 ID - ref26 ER - TY - JOUR AU - Watanabe, S. AU - Minegishi, Y. AU - Yoshizawa, H. AU - Maemondo, M. AU - Inoue, A. AU - Sugawara, S. PY - 2014 DA - 2014// TI - Effectiveness of gefitinib against non–small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q JO - J Thorac Oncol VL - 9 UR - https://doi.org/10.1097/JTO.0000000000000048 DO - 10.1097/JTO.0000000000000048 ID - Watanabe2014 ER - TY - JOUR AU - Otsuka, T. AU - MORI, M. AU - Yano, Y. AU - Uchida, J. AU - Nishino, K. AU - Kaji, R. PY - 2015 DA - 2015// TI - Effectiveness of tyrosine kinase inhibitors in Japanese patients with non-small cell lung cancer harboring minor epidermal growth factor receptor mutations: results from a multicenter retrospective study (HANSHIN oncology group 0212) JO - Anticancer Res VL - 35 ID - Otsuka2015 ER - TY - JOUR AU - Chiu, C. -. H. AU - Yang, C. -. T. AU - Shih, J. -. Y. AU - Huang, M. -. S. AU - Su, W. -. C. AU - Lai, R. -. S. PY - 2015 DA - 2015// TI - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations JO - J Thorac Oncol VL - 10 UR - https://doi.org/10.1097/JTO.0000000000000504 DO - 10.1097/JTO.0000000000000504 ID - Chiu2015 ER - TY - JOUR AU - Klughammer, B. AU - Brugger, W. AU - Cappuzzo, F. AU - Ciuleanu, T. AU - Mok, T. AU - Reck, M. PY - 2016 DA - 2016// TI - Examining treatment outcomes with Erlotinib in patients with advanced non–small cell lung cancer whose Tumors Harbor uncommon EGFR mutations JO - J Thorac Oncol VL - 11 UR - https://doi.org/10.1016/j.jtho.2015.12.107 DO - 10.1016/j.jtho.2015.12.107 ID - Klughammer2016 ER - TY - JOUR AU - Kwak, E. L. AU - Sordella, R. AU - Bell, D. W. AU - Godin-Heymann, N. AU - Okimoto, R. A. AU - Brannigan, B. W. PY - 2005 DA - 2005// TI - Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib JO - Proc Natl Acad Sci U S A VL - 102 UR - https://doi.org/10.1073/pnas.0502860102 DO - 10.1073/pnas.0502860102 ID - Kwak2005 ER - TY - JOUR AU - Yun, C. -. H. AU - Mengwasser, K. E. AU - Toms, A. V. AU - Woo, M. S. AU - Greulich, H. AU - Wong, K. -. K. PY - 2008 DA - 2008// TI - The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP JO - Proc Natl Acad Sci VL - 105 UR - https://doi.org/10.1073/pnas.0709662105 DO - 10.1073/pnas.0709662105 ID - Yun2008 ER - TY - JOUR AU - Ma, L. AU - Wang, D. D. AU - Huang, Y. AU - Wong, M. P. AU - Lee, V. H. AU - Yan, H. PY - 2015 DA - 2015// TI - Decoding the EGFR mutation-induced drug resistance in lung cancer treatment by local surface geometric properties JO - Comput Biol Med VL - 63 UR - https://doi.org/10.1016/j.compbiomed.2014.06.016 DO - 10.1016/j.compbiomed.2014.06.016 ID - Ma2015 ER - TY - STD TI - Ma L, Wang DD, Zou B, Yan H. An eigen-binding site based method for the analysis of anti-EGFR drug resistance in lung cancer treatment. IEEE/ACM Trans. Comput. Biol. Bioinform. 2017;14(5):1187–194. http://ieeexplore.ieee.org/abstract/document/7469333/. UR - http://ieeexplore.ieee.org/abstract/document/7469333/ ID - ref34 ER - TY - JOUR AU - Ma, L. AU - Zou, B. AU - Yan, H. PY - 2016 DA - 2016// TI - Identifying EGFR mutation-induced drug resistance based on alpha shape model analysis of the dynamics JO - Proteome Sci VL - 14 UR - https://doi.org/10.1186/s12953-016-0102-0 DO - 10.1186/s12953-016-0102-0 ID - Ma2016 ER - TY - JOUR AU - Wang, D. D. AU - Zhou, W. AU - Yan, H. AU - Wong, M. AU - Lee, V. PY - 2013 DA - 2013// TI - Personalized prediction of EGFR mutation-induced drug resistance in lung cancer JO - Sci Rep VL - 3 UR - https://doi.org/10.1038/srep02855 DO - 10.1038/srep02855 ID - Wang2013 ER - TY - JOUR AU - Zou, B. AU - Wang, D. D. AU - Ma, L. AU - Chen, L. AU - Yan, H. PY - 2016 DA - 2016// TI - Analysis of the relationship between lung cancer drug response level and atom connectivity dynamics based on trimmed Delaunay triangulation JO - Chem Phys Lett VL - 652 UR - https://doi.org/10.1016/j.cplett.2016.04.056 DO - 10.1016/j.cplett.2016.04.056 ID - Zou2016 ER - TY - JOUR AU - van Linden, O. P. AU - Kooistra, A. J. AU - Leurs, R. AU - de Esch, I. J. AU - de Graaf, C. PY - 2013 DA - 2013// TI - KLIFS: a knowledge-based structural database to navigate kinase–ligand interaction space JO - J Med Chem VL - 57 UR - https://doi.org/10.1021/jm400378w DO - 10.1021/jm400378w ID - van Linden2013 ER - TY - JOUR AU - Mordalski, S. AU - Kosciolek, T. AU - Kristiansen, K. AU - Sylte, I. AU - Bojarski, A. J. PY - 2011 DA - 2011// TI - Protein binding site analysis by means of structural interaction fingerprint patterns JO - Bioorg Med Chem Lett VL - 21 UR - https://doi.org/10.1016/j.bmcl.2011.09.027 DO - 10.1016/j.bmcl.2011.09.027 ID - Mordalski2011 ER - TY - JOUR AU - Deng, Z. AU - Chuaqui, C. AU - Singh, J. PY - 2004 DA - 2004// TI - Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein− ligand binding interactions JO - J Med Chem VL - 47 UR - https://doi.org/10.1021/jm030331x DO - 10.1021/jm030331x ID - Deng2004 ER - TY - JOUR AU - Deng, Z. AU - Chuaqui, C. AU - Singh, J. PY - 2006 DA - 2006// TI - Knowledge-based design of target-focused libraries using protein− ligand interaction constraints JO - J Med Chem VL - 49 UR - https://doi.org/10.1021/jm050381x DO - 10.1021/jm050381x ID - Deng2006 ER - TY - JOUR AU - Chupakhin, V. AU - Marcou, G. AU - Baskin, I. AU - Varnek, A. AU - Rognan, D. PY - 2013 DA - 2013// TI - Predicting ligand binding modes from neural networks trained on protein–ligand interaction fingerprints JO - J Chem Inf Model VL - 53 UR - https://doi.org/10.1021/ci300200r DO - 10.1021/ci300200r ID - Chupakhin2013 ER - TY - JOUR AU - Pérez-Nueno, V. I. AU - Rabal, O. AU - Borrell, J. I. AU - Teixidó, J. PY - 2009 DA - 2009// TI - APIF: a new interaction fingerprint based on atom pairs and its application to virtual screening JO - J Chem Inf Model VL - 49 UR - https://doi.org/10.1021/ci900043r DO - 10.1021/ci900043r ID - Pérez-Nueno2009 ER - TY - JOUR AU - Witek, J. AU - Smusz, S. AU - Rataj, K. AU - Mordalski, S. AU - Bojarski, A. J. PY - 2014 DA - 2014// TI - An application of machine learning methods to structural interaction fingerprints—a case study of kinase inhibitors JO - Bioorg Med Chem Lett VL - 24 UR - https://doi.org/10.1016/j.bmcl.2013.12.017 DO - 10.1016/j.bmcl.2013.12.017 ID - Witek2014 ER - TY - JOUR AU - Chuaqui, C. AU - Deng, Z. AU - Singh, J. PY - 2005 DA - 2005// TI - Interaction profiles of protein kinase− inhibitor complexes and their application to virtual screening JO - J Med Chem VL - 48 UR - https://doi.org/10.1021/jm049312t DO - 10.1021/jm049312t ID - Chuaqui2005 ER - TY - JOUR AU - Wassermann, A. M. AU - Geppert, H. AU - Bajorath, J. r. PY - 2009 DA - 2009// TI - Searching for target-selective compounds using different combinations of multiclass support vector machine ranking methods, kernel functions, and fingerprint descriptors JO - J Chem Inf Model VL - 49 UR - https://doi.org/10.1021/ci800441c DO - 10.1021/ci800441c ID - Wassermann2009 ER - TY - JOUR AU - Karplus, M. AU - McCammon, J. A. PY - 2002 DA - 2002// TI - Molecular dynamics simulations of biomolecules JO - Nat Struct Mol Biol VL - 9 UR - https://doi.org/10.1038/nsb0902-646 DO - 10.1038/nsb0902-646 ID - Karplus2002 ER - TY - JOUR AU - Lu, H. AU - Plataniotis, K. N. AU - Venetsanopoulos, A. N. PY - 2008 DA - 2008// TI - MPCA: multilinear principal component analysis of tensor objects JO - IEEE Trans Neural Netw VL - 19 UR - https://doi.org/10.1109/TNN.2007.901277 DO - 10.1109/TNN.2007.901277 ID - Lu2008 ER - TY - STD TI - Kobayashi Y, Mitsudomi T. Not all EGFR mutations in lung cancer are created equal: perspectives for individualized treatment strategy. Cancer Sci. 2016;107(9):1179–186. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021039/. UR - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021039/ ID - ref49 ER - TY - JOUR AU - Berman, H. M. AU - Westbrook, J. AU - Feng, Z. AU - Gilliland, G. AU - Bhat, T. N. AU - Weissig, H. PY - 2000 DA - 2000// TI - The protein data bank JO - Nucleic Acids Res VL - 28 UR - https://doi.org/10.1093/nar/28.1.235 DO - 10.1093/nar/28.1.235 ID - Berman2000 ER - TY - JOUR AU - Ma, L. AU - Wang, D. D. AU - Huang, Y. AU - Yan, H. AU - Wong, M. P. AU - Lee, V. H. PY - 2015 DA - 2015// TI - EGFR mutant structural database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib JO - BMC Bioinf VL - 16 ID - Ma2015 ER - TY - STD TI - Faith J. Interactive data exploration with targeted projection pursuit, Leonardo Electronic Almanac. 2009;16:6–7. http://nrl.northumbria.ac.uk/2706/. UR - http://nrl.northumbria.ac.uk/2706/ ID - ref52 ER - TY - STD TI - Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2010;39(suppl_1):D945–D950. https://academic.oup.com/nar/article/39/suppl_1/D945/2508687. UR - https://academic.oup.com/nar/article/39/suppl_1/D945/2508687 ID - ref53 ER - TY - JOUR AU - Yang, Z. AU - Hackshaw, A. AU - Feng, Q. AU - Fu, X. AU - Zhang, Y. AU - Mao, C. PY - 2017 DA - 2017// TI - Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: a meta-analysis JO - Int J Cancer VL - 140 UR - https://doi.org/10.1002/ijc.30691 DO - 10.1002/ijc.30691 ID - Yang2017 ER - TY - JOUR AU - Burotto, M. AU - Manasanch, E. E. AU - Wilkerson, J. AU - Fojo, T. PY - 2015 DA - 2015// TI - Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials JO - Oncologist VL - 20 UR - https://doi.org/10.1634/theoncologist.2014-0154 DO - 10.1634/theoncologist.2014-0154 ID - Burotto2015 ER - TY - JOUR AU - Bronte, G. AU - Rolfo, C. AU - Giovannetti, E. AU - Cicero, G. AU - Pauwels, P. AU - Passiglia, F. PY - 2014 DA - 2014// TI - Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects JO - Crit Rev Oncol Hematol VL - 89 UR - https://doi.org/10.1016/j.critrevonc.2013.08.003 DO - 10.1016/j.critrevonc.2013.08.003 ID - Bronte2014 ER - TY - JOUR AU - Leaver-Fay, A. AU - Tyka, M. AU - Lewis, S. M. AU - Lange, O. F. AU - Thompson, J. AU - Jacak, R. PY - 2011 DA - 2011// TI - ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules JO - Methods Enzymol VL - 487 UR - https://doi.org/10.1016/B978-0-12-381270-4.00019-6 DO - 10.1016/B978-0-12-381270-4.00019-6 ID - Leaver-Fay2011 ER - TY - JOUR AU - Maier, J. A. AU - Martinez, C. AU - Kasavajhala, K. AU - Wickstrom, L. AU - Hauser, K. E. AU - Simmerling, C. PY - 2015 DA - 2015// TI - ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB JO - J Chem Theory Comput VL - 11 UR - https://doi.org/10.1021/acs.jctc.5b00255 DO - 10.1021/acs.jctc.5b00255 ID - Maier2015 ER - TY - JOUR AU - Abagyan, R. AU - Totrov, M. AU - Kuznetsov, D. PY - 1994 DA - 1994// TI - ICM—a new method for protein modeling and design: applications to docking and structure prediction from the distorted native conformation JO - J Comput Chem VL - 15 UR - https://doi.org/10.1002/jcc.540150503 DO - 10.1002/jcc.540150503 ID - Abagyan1994 ER - TY - JOUR AU - Radifar, M. AU - Yuniarti, N. AU - Istyastono, E. P. PY - 2013 DA - 2013// TI - PyPLIF: python-based protein-ligand interaction fingerprinting JO - Bioinformation VL - 9 UR - https://doi.org/10.6026/97320630009325 DO - 10.6026/97320630009325 ID - Radifar2013 ER - TY - STD TI - Smith TC, Frank E. Introducing machine learning concepts with WEKA. Statistical Genomics: Methods and Protocols. 2016:353–78. https://link.springer.com/protocol/10.1007/978-1-4939-3578-9_17. UR - https://link.springer.com/protocol/10.1007/978-1-4939-3578-9_17 ID - ref61 ER -